Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2025-07-23 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) and specifically functions as a 'Correction Report' (정정신고) for a previously filed capital increase. It details the change in third-party allocation targets, including specific share counts and investor information. This falls under the category of announcements regarding new share issues or capital changes.
2025-07-23 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and details the outcome of shareholder votes regarding the appointment of directors. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the official results from a shareholder meeting.
2025-07-18 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of the Chief Executive Officer (CEO) of SCM Lifescience. It details the outgoing CEO, the incoming CEO, the reason for the change (resignation), and the date of the board resolution. This falls directly under the category of board or management changes.
2025-07-18 Korean
[기재정정]주주총회소집결의 (임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from SCM Lifescience regarding the 'Resolution to Convene a General Meeting of Shareholders' (specifically an Extraordinary General Meeting). It details the agenda items, including the appointment of directors, and provides specific information about the meeting date, location, and the candidates for the board. This falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on board appointments.
2025-07-03 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for SCM Life Science Co., Ltd. It includes the meeting agenda, details on director nominations, and management reports regarding business status and board activities. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and request their votes, which falls under the Proxy Solicitation & Information Statement category.
2025-07-03 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a '합병등종료보고서' (Report on Completion of Merger, etc.), which is a formal regulatory filing in South Korea used to announce the finalization of a corporate transaction, specifically an asset acquisition (자산양수도). It details the completion of the transaction between SCM Life Science and Kumho HT. Since this document reports on the completion of a specific corporate transaction (M&A/Asset acquisition), it falls under the category of M&A Activity (TAR).
2025-07-01 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.